Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Nov 7, 2024
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025
Cash position of $167 million, with operating runway into the fourth quarter of 2026
Read more at globenewswire.comNASDAQ:BOLD (7/25/2025, 8:00:01 PM)
1.265
+0.01 (+1.2%)
Find more stocks in the Stock Screener
